開拓藥業-B(09939.HK):治療新冠非住院患者試驗未達統計學顯着性令產品商業計劃延遲
開拓藥業-B(09939.HK)公佈其普克魯胺治療新冠非住院患者臨牀試驗,未達到統計學顯着性。開拓藥業創始人、董事長兼首席執行官童友之在電話會上表示,結果非常明顯顯示,該藥商業計劃延遲,對公司造成很大的一個問題。
童友之指,在推三個臨牀實驗的同時,公司比過去更加積極推緊急使用授權(EUA)的工作,普克魯胺治療新冠非住院患者研究的中期分析,得出的另外一個結論是藥物的安全性沒有問題,而此項是曾經在一些國家飽受質疑的事情,一個藥物安全性沒有問題,作爲公司更加有信心推動EUA的工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.